FDA May Soon Pull OTC Decongestants With Common but Ineffective Ingredient

If you’ve ever stood in the cold-and-flu aisle squinting at a wall of boxes like you’re decoding an ancient scroll,
you’re not alone. It’s basically a Choose-Your-Own-Adventure book… except every ending is “still congested” and you
paid $14.99 for the privilege.

Now the U.S. Food and Drug Administration (FDA) is moving to clean up one of the biggest “wait… does this even work?”
moments in over-the-counter (OTC) medicine: the widespread use of oral phenylephrinea common decongestant
ingredient that experts say doesn’t actually relieve nasal congestion when swallowed in the doses found in many products. ^[1]

Translation: some of the most familiar “congestion” boxes on the shelf may be reformulated, relabeled, or eventually removed
if phenylephrine’s oral form is no longer allowed under the OTC monograph system. ^[2]
And yes, it’s absolutely okay to feel personally betrayed by the words “Maximum Strength.”

What ingredient is the FDA targeting?

The ingredient at the center of the storm is phenylephrinespecifically, the oral form used in tablets,
capsules, and liquids marketed for nasal congestion. Phenylephrine is a decongestant that, in theory, narrows blood vessels in the nasal passages,
reducing swelling and helping you breathe through your nose.

In practice, the oral version runs into a problem that can be summed up as:
your body is extremely good at dismantling it before it can do its job. Modern evidence reviewed by FDA and its advisers
indicates that oral phenylephrine, at the nonprescription doses used in OTC products, doesn’t perform better than a placebo for nasal congestion. ^[3]

Where you’ve seen it (even if you didn’t notice)

Oral phenylephrine shows up in products aimed at “sinus,” “congestion,” or “severe” symptoms, including combination cold-and-flu medicines where it
sits alongside ingredients for fever, aches, cough, or runny nose. For example, some DayQuil/NyQuil “Severe” products list phenylephrine hydrochloride
as part of the active-ingredient lineup. ^[4]

That’s why this issue matters: even if you weren’t shopping for a “decongestant,” you may have bought one of these multi-symptom blends and assumed the
congestion part was covered. (It might not have been.)

What exactly is happening with the FDA right now?

The short version: FDA has proposed removing oral phenylephrine as a nasal decongestant ingredient from the OTC monograph for certain
cold/cough/allergy products, after an extensive review of the available data. ^[1]

The longer (but useful) version: in the OTC monograph system, “generally recognized as safe and effective” (GRASE) conditions determine which ingredients
can be marketed without going through the full new-drug approval process. FDA can update monographs through an administrative order process, including
proposed and final orders. ^[5]

In November 2024, FDA announced a proposal to end the use of oral phenylephrine for temporary relief of nasal congestion in OTC monograph
products. Importantly, FDA emphasized that, for now, companies could continue to market products containing oral phenylephrine while the
process plays out. ^[1]

A key detail: proposed doesn’t mean “pulled tomorrow”

FDA’s OTC monograph portal for the phenylephrine proposal describes it as a proposed order and notes a public comment window that ran through
May 7, 2025. ^[2] That comment period matters because it’s the official channel for data, arguments, and concerns from industry, clinicians,
and consumers.

Practically speaking, the shelves don’t clear overnight. A final order (if FDA issues one) typically comes with implementation timing so manufacturers can
reformulate or transition products. Some regulatory analyses have noted that effective dates can land well after the final order is published. ^[6]

Why experts say oral phenylephrine doesn’t work

The scientific explanation is less mysterious than it feels when you’re staring at a box promising “fast relief”:
oral phenylephrine is significantly metabolized in the gut and liver, which limits how much active drug reaches the bloodstreamand therefore how much can
reach the nasal tissues to reduce congestion. ^[7]

FDA’s scientific review and advisory discussions focused on modern clinical trials and pharmacokinetic evidence. In September 2023, FDA’s Nonprescription Drugs
Advisory Committee reviewed the evidence and voted unanimously that the current scientific data do not support the effectiveness of oral phenylephrine at
monograph doses. ^[3]

“So just take a higher dose?” (Not so fast.)

This is the part where your inner DIY pharmacist tries to negotiate with reality. The issue isn’t that phenylephrine is “almost” effective and just needs a
little boost. The FDA review and outside experts have discussed that higher doses raise safety concerns, including cardiovascular effects like increased blood
pressure, and still may not reliably deliver meaningful congestion relief. ^[3]

In other words: the “fix” isn’t as simple as “more.” The FDA’s conclusion is essentially: at OTC doses it doesn’t work, and pushing doses higher isn’t a
comfortable solution. ^[1]

Will this affect all phenylephrine products?

Noand this is one of the easiest points to misunderstand.
The FDA’s action focuses on orally administered phenylephrine in OTC monograph products used for nasal congestion. ^[1]

Phenylephrine used in nasal sprays is a different story; the proposal is about the oral form, not every phenylephrine product in existence. ^[1]
(Your nose gets a direct delivery in sprays; your digestive system doesn’t get to intercept the package first.)

What about combo products like DayQuil, NyQuil, and “Severe” cold meds?

Here’s the nuance: many products contain phenylephrine alongside ingredients that do address other symptoms, such as acetaminophen for fever/pain or
dextromethorphan for cough. FDA has explicitly noted that the presence of oral phenylephrine doesn’t change how the other active ingredients work for the symptoms
they’re intended to treat. ^[1]

If oral phenylephrine is removed from the monograph, manufacturers could:

• reformulate with a different decongestant option (where appropriate),
• drop the “congestion” claim and adjust labeling/marketing,
• or discontinue certain versions entirely.

The “pull” might look less like a dramatic recall and more like a slow rearranging of the cold aislenew boxes, updated ingredients, and fewer products that
promise decongestion without delivering it.

Why phenylephrine became the decongestant you see everywhere

If you’re thinking, “How did an ineffective ingredient become a superstar?”that’s a fair question. The answer includes a major policy shift around
pseudoephedrine (the decongestant many people swear actually works).

Under federal restrictions aimed at reducing methamphetamine production, products containing pseudoephedrine were moved out of open retail accessmeaning you
often have to request them at the pharmacy counter, show ID, and follow purchase limits. FDA describes legal requirements for products containing pseudoephedrine,
ephedrine, and related ingredients under the Combat Methamphetamine Epidemic Act framework. ^[8]

As pseudoephedrine became less “grab-and-go,” phenylephrine became the easy-to-stock, on-the-shelf alternative in many OTC productsespecially combination cold
medicines. ^[3]

What to buy instead if you want real congestion relief

First, a quick reality check: “nasal congestion” can be caused by colds, flu, allergies, dry air, sinus inflammation, or irritants. No single option is perfect
for everyone. Still, there are practical, evidence-based approaches that can help.

1) Non-drug basics that actually help (and won’t mess with your blood pressure)

The simplest options are often underrated because they aren’t packaged in shiny boxes that yell “SEVERE.” The CDC recommends supportive measures such as rest,
fluids, humidified air, saline nasal spray/drops, and steam. ^[9]

Saline irrigation (spray, rinse, or neti-style systems used properly with sterile/distilled water) can thin mucus and improve nasal comfortespecially if your
main issue is thick, sticky congestion rather than purely swollen nasal passages.

2) Pseudoephedrine (the “behind-the-counter” decongestant)

Pseudoephedrine remains available but is often stored behind the pharmacy counter due to legal controls. ^[8] For many adults, it provides more noticeable
congestion relief than oral phenylephrine. But it can also cause side effects (like jitteriness, insomnia, or increased heart rate) and may be inappropriate for people
with certain medical conditions or medication interactions.

If you have high blood pressure, heart rhythm issues, glaucoma, or you’re taking medications that could interact, it’s smart to ask a pharmacist or clinician before
choosing an oral decongestant.

3) Nasal sprays: helpful, but don’t get greedy

Topical nasal decongestant sprays (like oxymetazoline) can work quickly because they’re applied where the problem is. The trade-off is the risk of “rebound congestion”
(rhinitis medicamentosa) if you overuse them. Medical references describe rebound congestion as inflammation caused by overuse of topical nasal decongestants. ^[10]

A practical rule many clinicians follow: use these sprays for the shortest time possible (often no more than a few days) unless directed otherwise by a healthcare
professional. If you’ve ever said, “I only used it because I couldn’t breathe,” welcome to the rebound clubmembership is free, but cancellation is annoying.

4) If allergies are the culprit: consider steroid or antihistamine nasal sprays

If your congestion is mostly from allergies, decongestants may be the wrong tool. Intranasal steroid sprays and certain antihistamine sprays can reduce inflammation and
congestion over time. These aren’t instant like a decongestant spray, but they can be more effective for allergy-driven stuffiness.

(And if your symptoms last weeks, return every season, or include itchy eyes and lots of sneezing, “allergies” becomes a strong suspect.)

How to spot phenylephrine on a Drug Facts label

If oral phenylephrine is removed from the monograph in a final order, products will change over time. But right now, it’s still widely present. FDA’s consumer guidance
on OTC oral phenylephrine points people to read the Drug Facts label and understand active ingredients. ^[7]

Look for:

• Phenylephrine HCl (phenylephrine hydrochloride)
• Phenylephrine bitartrate

If a product is a “multi-symptom” medicine, check whether it contains a decongestant at alland if it does, which one. You might find you’re paying for an ingredient
you don’t benefit from, bundled with others you do.

What about kids and decongestants?

Cold medicine decisions are more delicate for children. FDA consumer guidance states it does not recommend OTC medicines for cough and cold symptoms in children younger
than 2 due to the risk of serious side effects, and notes that manufacturers voluntarily label many cough/cold products with “Do not use in children under 4 years of age.” ^[11]

For kids, supportive care (fluids, rest, saline drops/spray, humidified air) is often the main strategy unless a pediatric clinician recommends otherwise. ^[9]

What happens nextand when could shelves actually change?

As of the latest FDA public materials available, the agency has proposed removing oral phenylephrine from the applicable OTC monograph conditions and has gone through a
public comment process. ^[2] After reviewing comments, FDA can decide whether to issue a final order.

Some reporting and regulatory commentary suggests the timeline could extend well beyond the proposal stagepotentially into 2026 for a final decision and later for full
market transition, depending on effective dates and reformulation pace. ^[6]

Meanwhile, trade groups have criticized the proposal, arguing consumers have relied on oral phenylephrine for decades and expressing disappointment in FDA’s shift. ^[12]
Othersincluding clinician groupshave urged FDA to remove ineffective oral phenylephrine products sooner rather than later. ^[7]

Conclusion: the cold aisle is about to get a reality check

If you take nothing else from this: oral phenylephrine is widely used, but modern evidence reviewed by FDA indicates it doesn’t effectively relieve nasal congestion
at OTC doses. ^[1] The FDA’s proposal signals a push toward making “congestion relief” mean what it says.

In the near term, you’ll still see oral phenylephrine products on shelves. Over the longer term, you may see reformulations, label changes, and fewer products that quietly
charge you for an ingredient that’s basically doing interpretive dance in your digestive tract.

If you want more reliable congestion relief, consider options like supportive care, saline, allergy-targeted sprays, or pseudoephedrine (when appropriate and safe). And when
you’re unsure, a pharmacist can often save you money, time, and the emotional damage of realizing your “decongestant” wasn’t actually decongesting.

Experiences From the Real World (and What People Wish They’d Known)

Let’s talk about the part that doesn’t show up on a clinical trial spreadsheet: the lived experience of being congested, tired, and mildly furious while your cart contains
“SEVERE MAXIMUM ULTRA” cold medicine that somehow isn’t doing the one thing you bought it for.

Experience #1: The “I can’t breathe, so I bought the loudest box” moment.
A very common scenario goes like this: you wake up stuffed up, your nose feels like it’s packed with wet cement, and you have exactly one goalairflow. You head to the store,
find a product that promises “congestion relief,” take it faithfully, and… nothing. Your cough might calm down, your fever might improve, but your nose remains committed to
being decorative rather than functional.

People often describe this as confusing because they do feel somethingsometimes a little dry mouth, maybe a slight “medicated” sensationso it seems like the product
is active. What they’re often feeling is the effect of the other ingredients (pain reliever, cough suppressant, antihistamine) while the phenylephrine portion quietly fails its
audition for “Best Supporting Decongestant.” The FDA has noted that in combination products, other active ingredients still work for their intended symptoms even if phenylephrine
doesn’t handle congestion. ^[1]

Experience #2: The airport test.
Congestion loves to show off during traveldry cabin air, pressure changes, and the universe’s desire to make your ears feel like they’re underwater. A lot of travelers grab an
OTC “congestion” product before flying, expecting relief. If that product relies on oral phenylephrine, the results may be underwhelming. That’s when people start swapping tips in
waiting areas like an underground support group: “Try saline,” “Use a humidifier at night,” “Ask the pharmacist for the behind-the-counter stuff.”

The behind-the-counter reference is usually pseudoephedrine, which is subject to legal purchase requirements and is not typically left out on open shelves. FDA explains that
pseudoephedrine products are restricted in retail access under federal rules designed to prevent diversion for meth production. ^[8]

Experience #3: The nasal spray rebound trap.
After oral meds disappoint, many people move to nasal spraysand often find quick relief. Then comes the temptation: “If one spray is good, two is better, and five is basically
a personality.” Unfortunately, overuse of topical nasal decongestant sprays can lead to rebound congestion (rhinitis medicamentosa), where the nose feels even more blocked when the
medication wears off. Medical references describe rebound congestion as a real phenomenon tied to overuse of these sprays. ^[10]

This is where experience turns into wisdom: the best spray is the one you use correctly and briefly, not the one you become emotionally dependent on. People who’ve gone through rebound
congestion often say they wish they’d started with saline or allergy-targeted options (when allergies were the true cause) instead of “panic-spraying” their way into a longer problem.

Experience #4: Parenting + cold medicine = a masterclass in label-reading.
Parents and caregivers frequently describe the cold aisle as extra stressful because kids’ symptoms feel urgent, sleep disappears, and everything is labeled with tiny print while your brain
is running on fumes. FDA guidance warns against using OTC cough and cold products in children under 2 and notes voluntary labeling that says not to use many of these products in children under 4. ^[11]
In real life, that translates to a lot of parents pivoting to supportive care: saline drops, humidifiers, fluids, and comfort measures. ^[9]

The overarching “experience lesson” is surprisingly simple: match the product to the symptom and the cause. If your biggest problem is congestion from a cold, options like saline,
humidified air, and (when safe) an effective decongestant strategy can help. If your congestion is allergy-driven, anti-inflammatory nasal sprays may make more sense than chasing quick fixes. And if
your symptoms are severe, persistent, or accompanied by red flags (high fever, shortness of breath, chest pain, significant facial pain, dehydration, or symptoms lasting unusually long), it’s time to
bring in a clinician instead of buying your seventh box of hope.

Finally: a gentle emotional truth. Many people feel annoyed when they learn an ingredient marketed for congestion relief may not actually work orally. That feeling is valid. The upside is that this FDA
moveif finalizedcould make the cold aisle clearer, more honest, and less like a game of “guess which ingredient is doing anything.” ^[1]

Footnotes

1. FDA press announcement and related FDA materials on the proposed removal of oral phenylephrine from OTC monograph conditions.
2. FDA OTC monograph order detail (OTC000036) and comment-period details.
3. Advisory committee review and reporting on the unanimous vote regarding oral phenylephrine effectiveness.
4. Example OTC labeling showing phenylephrine hydrochloride in combination cold-and-flu products (e.g., certain “Severe” formulations).
5. FDA overview of the OTC monograph/administrative order process.
6. Regulatory and news analysis discussing timing and implementation mechanics for a final order.
7. FDA key information page and/or scientific review documents discussing evidence and rationale.
8. FDA legal requirements describing restricted retail access for pseudoephedrine products.
9. CDC guidance on common cold supportive care strategies.
10. Medical references describing rebound congestion (rhinitis medicamentosa) associated with overuse of topical nasal decongestants.
11. FDA consumer guidance on cough/cold medicines in children and age-related warnings.
12. Industry response to FDA’s proposed order.